Thus, we asked whether FATP2 inhibition enhanced the anti-tumor activity of conventional chemotherapies, such as etoposide (VP16, a topoisomerase II inhibitor) or temozolomide (TMZ, a DNA alkylating agent), which are used as induction or relapse therapies. The gene discussed is SLC27A2; the disease is neoplasm.